Biotech Industry News
A collection of Biotech latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Why This Hair-Loss Biotech Is Killing It
This year's crop of biotechnology IPOs features an unusual star in an industry better known for targeting severe diseases: Veradermics, whose shares have rocketed on the potential of its hair-loss pill. New Haven, Conn.-based Veradermics went…
BiomedVC Adds Three Renowned Entrepreneurs as Advisors for Fund IV to Champion Early-Stage European Biotech
Claudia Ulbrich, (ex-Cardior), David Urech (ex-Numab), and Ulf Grawunder (ex-NB-Therapeutics) join BiomedVC's team of entrepreneurial leaders bringing an outstanding combined track record of founding, scaling, and exiting billion dollar biotechs…
How Hong Kong's role as innovation hub helps healthcare and biotech firms
One major milestone was the establishment of the Greater Bay Area International Clinical Trial Institute in 2024. Located at the Hong Kong-Shenzhen Innovation and Technology Park, it serves as a platform for cross-border, multi-centre clinical…
US loses 'regenerative capacity' without foreign talent, biotech CEO says
Restricting the ability to bring in the best foreign talent will hinder companies' growth and in turn the US economy, the head of US biotech company, Flagship Pioneering, said at Semafor World Economy in Washington, DC. People who immigrated to the…
Top Biotech Stocks To Watch Today - April 16th
The Often-Missed Corner of Healthcare That Wall Street Is Loving Danaher, Vertex Pharmaceuticals, argenex, Moderna, United Therapeutics, Capstone Therapeutics, and Spyre Therapeutics are the seven Biotech stocks to watch today, according to…
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Short Interest Update
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) was the target of a large increase in short interest in March. As of March 31st, there was short interest totaling 2,304,530 shares, an increase of 26.9% from the March 15th total of…
Legend Biotech (NASDAQ:LEGN) Trading 6.3% Higher - Still a Buy?
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Get Free Report) traded up 6.3% on Thursday. The company traded as high as $21.20 and last traded at $21.8180. 340,553 shares were traded during trading, a decline of 84% from the average…
Q2 EPS Estimates for Legend Biotech Lowered by HC Wainwright
CPI Data Sparks Rally in Biotech Stocks Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Free Report) - Equities researchers at HC Wainwright lowered their Q2 2026 earnings estimates for shares of Legend Biotech in a report issued on…
FDA Peptide Review, A Big Moment For Hims & Hers Stock (NYSE:HIMS)
Hims & Hers faces a pivotal regulatory moment as the FDA reconsiders compounded peptide therapies, especially GLP-1 drugs like semaglutide. A permissive FDA framework could legitimize compounded peptides, unlocking renewed growth and reversing the…
Jensen Huang explains why Nvidia invests in tons of companies, instead of trying to pick winners
Jensen Huang says Nvidia invests in a lot of tech companies, instead of selecting a handful, for a reason. 'There are so many great, amazing foundation model companies, and we try to invest in all of them,' he said on an episode of the 'Dwarkesh'…
Eurobio scientific signs definitive agreement to acquire CareDx's transplant Lab Product division
EUROBIO SCIENTIFIC SIGNS DEFINITIVE AGREEMENT TO ACQUIRE CAREDX's TRANSPLANT LAB PRODUCT DIVISION Acquisition of CareDx's ‘lab products' portfolio creates new opportunities for growth and innovation in the fast growing transplant diagnostics…
Vanguards of Health Care: Roivant and the Art of Clinical Value
“In biotech all of the ideas sound amazing and most of them don't work.” Roivant CEO Matt Gline joins Bloomberg Intelligence analyst Sam Fazeli to explain how the company tries to tilt those odds through an unconventional model built…
TME Pharma Announces Publication of NOX-A12 'Triple Therapy' Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications
TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications Berlin, Germany, April 16, 2026, 08.00am CET – TME Pharma N.V. (Euronext Growth Paris:…
Is Vertex Pharmaceuticals' Empire in Trouble?
Over the past 10 years, Vertex Pharmaceuticals (VRTX 1.91%) has delivered market-beating returns. The company owes this performance to its dominance in the cystic fibrosis (CF) drug market. Vertex Pharmaceuticals essentially has a monopoly in this…
7 Indian firms in race, experts eye cheaper Keytruda version in 2 years
The lack of access to Keytruda is one of the key findings of an investigation by The Indian Express in association with the International Consortium of Investigative Journalists (ICIJ) into how a growing multi-city counterfeit racket in the drug is…
Receive a Daily briefing on Biotech Industry News
Get Started